Acute myeloid leukemia in children. Prospects for the optimization of treatment (review)
https://doi.org/10.17650/2311-1267-2017-4-1-30-36
Abstract
Acute myeloid leukemia (AML) occurs in frequency 1.5 per 100 000 children and occupy 15–20 % in the structure of pediatric acute leukemia. In comparison with adults, pediatric AML usually a primary disease; clonal evolution of myeloproliferative disorders is rare situation in clinical course of the disease. Pediatric AML classification based on combination of morphology, cytochemistry, immune phenotyping and molecular genetics and situated in the process of permanent revision. Doctrine of AML treatment, excluding acute promyelocytic leukemia, was not changed during last 30 years, but the survival rate increased from 40 to 60–65 % because of stratification of patients on risk groups, intensification of chemotherapy, application of epigenetic/target therapy, improvement of supportive care and widening of indications for hematopoietic stem cell transplantation in the clinical program of treatment.
Children in the age under 2 years old with AML is the unique group of patients with different biology of process, genetic aberrations, concentration of unfavorable risk factors and expressed predisposition to therapeutic toxicity. Progress of the treatment for this subgroup with usage of risk-based protocols of treatment during the last 10 years leads to change of prognosis – now the prognosis is the same in comparison with more adult groups of patients.
Thus, 25–30 % of patients with AML in the age of 0–18 years old can be faced with relapse of leukemia, 5–10 % will die because of complications of disease and/or side effects of therapy. Prospects of treatment optimization for children are connected with target therapy of different genetic variants of AML, like for promyelocytic leukemia or chronic myeloid leukemia, as well as in decreasing of the toxicity of therapy. Review of international studies for AML treatment for children is presented in this article as well as discussion on prospect of optimization of treatment.
About the Author
A. G. Rumyantsev
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997
Russian Federation
1 Samory Mashela St., Moscow, 117997
References
1. Литвиненко Н.П., Шнейнер М.М., Савва Н.Н. и др. Лечение острого миелолейкоза у детей по протоколу ОМЛ-2000; предварительные результаты исследования кооперированной группы «Россия–Беларусь». Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2006;5(3):23–32. [Litvinko N.P., Shneider M.M., Sawa N.N. et al. Treatment of acute myeloblastic leukemia in children by the AML-MM-2000 protocol: Preliminary results of cooperative Russian–Belarus studies. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/ Oncology and Immunopathology 2006;5(3):23–32. (In Russ.)].
2. Шнейдер М.М. Эффективность риск-адаптированной терапии острого миелоидного лейкоза у детей с использованием режимов интенсивного тайминга и трансплантации гемопоэтических стволовых клеток. Автореф. дис. … канд. мед. наук. М., 2008. 57 с. [Shneider M.M. The effectiveness of risk-adapted therapy of acute myeloid leukemia in children with intensive modes of timing and hematopoietic stem cell transplantation. Dissert. PhD. M., 2008. 57 p. (In Russ.)].
3. Немировченко В.С. Роль вальпроевой и полностью транс-ретиноевой кислот в лечении детей с острыми миелоидными лейкозами. Автореф. дис. … канд. мед. наук. М., 2008. 28 с. [Nemirovchenko V.S. The role of valproic and all-trans retinoic acid in the treatment of children with acute myeloid leukemia. Dissert. PhD. M., 2008. 28 p. (In Russ.)].
4. Баровская Ю.А. Современные аспекты диагностики и лечения острого миелоидного лейкоза у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015;14(3):48–54. [Barovskaya Yu.A. Diagnosis and treatment of acute myeloid leukemia in children: Modern aspects. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2006;5(3):23–32. (In Russ.)].
5. Tsukimoto I., Tawa A., Horibe K. et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009;27(24):4007–13.
6. Rubnitz J.E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood AML: results of the AML02 multicentre trial. Lancet Oncol 2010;11(6):543–52.
7. Gibson B.E., Webb D.K., Howman A.J. et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011;155(3):366–76.
8. Creutzig U., Zimmermann M., Bourquin J.P. et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013;122(1):37–43.
9. Pession A., Masetti R., Rizzari C. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013;122(2):170–8.
10. Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937–51.
11. Masetti R., Vendemini F., Zama D. et al. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr 2015;3:37.
12. Rubnitz J.E., Inaba H. Childhood acute myeloid leukaemia. Br J Haematol 2012;159(3):259–76.
13. Creutzig U., Zimmermann M., Bourquin J.P. et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012;26(4):654–61.
14. Balgobind B.V., Hollink I.H., Arentsen-Peters S.T. et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011;96(10):1478–87.
15. Hollink I.H., van den Heuvel-Eibrink M.M., Arentsen-Peters S.T. et al. NUP98/ NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011;118(13):3645–56.
16. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011;152(2):141–54.
17. Annesley C.E., Brown P. Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 2015;6(2):61–79.
18. Juhl-Christensen C., Ommen H.B., Aggerholm A. Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatr Blood Cancer 2012;58(4):525–31.
19. Langemeijer S.M., Jansen J.H., Hooijer J. et al. TET2 mutations in childhood leukemia. Leukemia 2011;25(10):189–92.
20. Inaba H., Rubnitz J.E., Coustan-Smith E. et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011;29(24):3293–300.
21. Watt T.C., Cooper T. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. Pediatr Blood Cancer 2012;59(4):756–7.
22. Smith C.C., Wang Q., Chin C.S. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012;485(7397):260–3.
23. Ravandi F., Cortes J.E., Jones D. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28(11):1856–62.
24. Deshpande A.J., Chen L., Fazio M. et al. Leukemic transformation by the MLLAF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013;121(13):2533–41.
25. Hasle H., Abrahamsson J., Forestier E. et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 2012;120(5):978–84.
26. Gamis A.S., Aplenc R., Alonzo T.A., Sung L. et al. Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves EventFree Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531. Blood 2013;122:345–55.
27. Ravandi F., Estey E.H., Appelbaum F.R. et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012;30(32):3921–3.
28. Gasiorowski R.E., Clark G.J., Bradstock K., Hart D.N. Antibody therapy for acute myeloid leukaemia. Br J Haematol 2014;164(4):481–95.
29. Gill S., Tasian S.K., Ruella M. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014;123(15):2343–54.
30. Lynn R.C., Poussin M., Kalota A. et al. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor expressing T-cells. Blood 2015;125(22):3466–76.
31. Cooper T.M., Alonzo T.A., Gerbing R.B. et al. AAML0523: a report from the Children’s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer 2014;120(16):2482–9.
32. Phillips C.L., Davies S.M., McMasters R. et al. Low dose decitabine in very high risk relapsed or refractory AML in children and young adults. Br J Haematol 2013;161(3):406–10.
33. Pulsipher M.A., Langholz B., Wall D.A. et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 2014;123(13):2017–25.
34. Daver N., Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology 2012;17 Suppl 1:S59–62.
35. Попа А.В., Горохова Е.В., Флейшман Е.В. и др. Эпигенетическая терапия – важная составляющая в лечении детей, больных острым миелоидным лейкозом. Клиническая онкогематология 2011;4(1):20–6. [Popa A.V., Gorokhova E.V., Fleyshman E.V. et al. Epigenetic therapy – an important component in the treatment of children with acute myeloid leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2011;4(1):20–6. (In Russ.)].
36. de Rooij J.D.E., Zwaan C.M., van den Heuvel-Eibrink M. Pediatric AML: From Biology to Clinical Management. J Clin Med 2015;4(1):127–49.
37. Рубнитц Дж.Е. Современные стратегии лечения острого миелоидного лейкоза. Российский журнал детской гематологии и онкологии 2016;3(3):47–51. [Rubnitz J.E. Modern strategies in AML treatment. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2016;3(3):47–51. (In Russ.)].
Review
For citations:
Rumyantsev A.G. Acute myeloid leukemia in children. Prospects for the optimization of treatment (review). Russian Journal of Pediatric Hematology and Oncology. 2017;4(1):30-36. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-1-30-36
Views:
2895
Email this article 